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Abstract
Background: The problem of predicting whether a drug combination of arbitrary orders is likely to induce
adverse drug reactions is considered in this manuscript.
Methods: Novel kernels over drug combinations of arbitrary orders are developed within support vector
machines for the prediction. Graph matching methods are used in the novel kernels to measure the similarities
among drug combinations, in which drug co-medication patterns are leveraged to measure single drug
similarities.
Results: The experimental results on a real-world dataset demonstrated that the new kernels achieve an area
under the curve (AUC) value 0.912 for the prediction problem.
Conclusions: The new methods with drug co-medication based single drug similarities can accurately predict
whether a drug combination is likely to induce adverse drug reactions of interest.
Keywords: drug-drug interaction prediction; drug combination similarity; co-medication; graph matching
Introduction
Drug-Drug Interactions (DDIs) and the associated Ad-
verse Drug Reactions (ADRs) represent a consistent
detriment to the public health in the United States.
DDIs have accounted for approximately 26% of the
ADRs, occurred among 50% of the hospitalized pa-
tients [1], and caused nearly 74,000 emergency room
visits and 195,000 hospitalizations annually in the
US [2]. Apart from these, because of the common prac-
tice of co-medication among elderly Americans, par-
ticularly co-medication of more than two drugs, the
high-order drug-drug interactions and their associated
ADRs have imposed significant scientific and public
health challenges. The National Health and Nutrition
Examination Survey [3] reports that more than 76%
of the elderly Americans take two or more drugs every
day. Another study [4] estimates that about 29.4% of
elderly American patients take six or more drugs every
day. However, for most of such high-order DDIs, their
mechanisms are unknown.
In this manuscript, novel approaches to predicting
whether high-order drug combinations are likely to in-
duce ADRs are presented. The prediction problems are
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formulated as a binary classification problem and sup-
port vector machines (SVMs) are used for the pre-
diction. Novel kernels over drug combinations of ar-
bitrary orders are developed within the framework of
SVMs. These kernels are constructed using drug co-
medication information to measure single drug similar-
ities and graph matching on drug combination graphs
to measure drug combination similarities. A compari-
son on the new kernels with other convolutional kernels
and probabilistic kernels on drug combinations is also
conducted. The experimental results demonstrate that
the new kernels outperform the others and can accu-
rately predict whether a drug combination is likely to
induce ADRs of interest with an AUC value 0.912. To
the best of our knowledge, this manuscript represents
the first effort in predicting DDIs for drug combina-
tions of arbitrary orders.
Background
Drug-drug interactions
Significant research efforts have been dedicated to de-
tect pairwise drug-drug interactions (DDIs) [5, 6] in
recent years. Existing methods either extract DDI
pairs mentioned in medical literature or Electronic
Health Records (EHRs) [4], or predict/score DDI pairs
from various drug/target information [7]. While most
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of the existing DDI studies are focused on interac-
tions between a pair of drugs (i.e., order-2 DDIs),
understanding high-order DDIs and their associated
ADRs has attracted increasing attention recently [2,
8]. These emerging methods on high-order DDI stud-
ies are largely focused on how to discover high-order
DDIs through mining frequent itemsets (i.e., drug com-
binations) from EHRs efficiently. Most recent work
also includes pattern discovery from directional high-
order DDIs [9] and directional high-order DDI predic-
tion [10].
Graph matching
Graph matching is to find the optimal vertex corre-
spondence between two graphs [11, 12]. Graph match-
ing problems can be broadly classified into two cat-
egories. The first category is exact graph matching,
which is to find the graph and subgraph isomorphisms
so that the mapping of vertices between two graphs is
bijective and edge-preserving (i.e., vertices connected
by an edge in one graph are mapped to vertices in
the other graph that are also connected by an edge).
The second category is inexact graph matching, which
allows errors (e.g., different types of matched ver-
tices in attributed graphs) during matching, and thus
it is to minimize the total errors in finding optimal
graph matching. Typical algorithms for graph match-
ing include spectral methods [13], probabilistic meth-
ods [14], tree search [15], etc.
Definitions and notations
We use di to represent a drug, andD
k = {d1, d2, · · · , dk}
to represent a combination of k drugs, where k is the
number of unique drugs in Dk (i.e., k = |Dk|) and
thus the order of Dk. A drug combination Dk is de-
fined when the drugs and only the drugs in Dk are
taken simultaneously. There are no orderings among
the drugs in a drug combination. When no ambigu-
ity is raised, we drop the superscript k in Dk and
represent a drug combination as D. An event is re-
ferred to as a patient taking a drug combination. In
addition, in this manuscript, all vectors (e.g., c) are
represented by bold lower-case letters and all matri-
ces (e.g., X) are represented by upper-case letters.
Row vectors are represented by having the transpose
superscript T, otherwise by default they are column
vectors. Table 1 summarizes the important notations
in the manuscript.
Methods
We formulate the problem of predicting whether high-
order drug combinations induce a particular ADR as
a binary classification problem, and solve the classifi-
cation problem within the framework of kernel meth-
ods and support vector machines (SVMs). In this
manuscript, we consider myopathy as the ADR in par-
ticular. The central concept of SVM-based classifica-
tion methods is that “similar” instances are likely to
share similar labels, and thus the key is to capture
and measure the “similarities” among instances (i.e.,
drug combinations in our ADR prediction problem)
via kernels. In the case of drug combinations, we hy-
pothesize that if two drug combinations share simi-
lar pharmaceutical, pharmacokinetic and/or pharma-
codynamic properties, they may induce similar ADRs.
Therefore, the question boils down to effectively rep-
resenting and measuring the similarities in terms of
such properties. To this end, we develop various ker-
nels over drug combinations. A key property of such
kernels as will be discussed later is that they are able to
deal with drug combinations of arbitrary orders. These
kernels are constructed using single drug similarities,
which incorporate various drug information that could
relate to DDIs. Here we decompose the discussion on
such kernels from three aspects: 1). single drug simi-
larities (SDS) as in Section , 2). our new kernel based
on matching similar drugs in drug combination graphs
in Section , and 3). other convolutional kernels [16] in
Section . Given these kernels, we further employ the
freely available SVM-Light software to build up the
binary classifiers and conduct our experiments based
on such classifiers [17].
Single drug similarities
We use two different approaches to measuring single
drug similarities (SDS). The first approach measures
single drug similarities based on their intrinsic proper-
ties that can be represented by their 2D structures [18].
The second approach measures the similarities in a
more data-driven fashion based on the co-occurrence
patterns among drugs.
SDS from drug 2d structures
A straightforward way to measure SDSs between two
drugs is to look at their structures, which ultimately
determine their physicochemical properties. We use
Extended Connectivity Fingerprints (ECFP) [19] of
length 2,048 to represent drug 2D structures. Each of
the fingerprint dimensions corresponds to a substruc-
ture among the drugs of interest. The binary values
in the fingerprints represent whether a drug has the
corresponding substructure or not. We use a vector
xi ∈ R2048 to represent the fingerprint for drug di.
The SDS between two drugs from their 2D structures,
denoted as SDS2d, is calculated as the Tanimoto coef-
ficient between their ECFP fingerprints [20]. Tanimoto
coefficient between two sets is defined as follows,
Tanimoto(S1, S2) =
|S1 ∩ S2|
|S1|+ |S2| − |S1 ∩ S2|
, (1)
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where |S| is the cardinality of set S. Thus, SDS2d is
defined as
SDS2d(di, dj) = Tanimoto({xi}, {xj}), (2)
where {xi} represents the set of substructures that di
has in its fingerprint xi.
SDS based on co-medications
We develop a new approach to measuring the SDS be-
tween two drugs by looking at whether they are often
involved in co-medications with similar other drugs,
respectively. The hypothesis is that drugs that are re-
spectively taken together with other similar drugs may
share similar therapeutic purposes and target similar
therapeutic targets, and thus behave similarly in in-
ducing ADRs. Such data-driven co-medication based
SDSs have a potential advantage over SDS2d in that
they leverage the signals from ADRs information di-
rectly that may not be captured or explained by drug
2D structures or other features on individual drugs.
Such co-medication based SDS is denoted as SDScm.
We use two vectors c+i ∈ R
n and c−i ∈ R
n (n
is the total number of drugs) to represent the co-
medication information for drug di. The j-th dimen-
sion (j = 1, · · · , n) in c+i /c
−
i corresponds to drug dj,
and the value on the j-th dimension in c+i /c
−
i is the
co-medication frequency of di and dj in all the events
with/without ADRs. Both c+i and c
−
i values are then
normalized into probabilities. The normalized c+i and
c
−
i are further concatenated into one vector ci, that
is, ci = [c
+
i ; c
−
i ], for di. The SDScm between drug di
and dj is calculated as the cosine similarity between
ci and cj . The reason why we use c
+
i and c
−
i to con-
struct ci instead of co-medication frequencies from all
events with and without ADRs together is that the co-
medication patterns from the two types of events can
be very different, and thus one unified co-medication
vector for both of them could not necessarily capture
discriminative information among drugs.
Drug combination kernels from graph matching
We formulate the problem of comparing drug combi-
nation similarities through matching drug combination
graphs, and develop a graph-matching based kernel for
drug combination similarities. Specifically, for a drug
combination Dp = {dp1, dp2, · · · , dpkp}, we construct a
complete graph Gp of kp nodes, in which each node
represents a drug in Dp, and all the nodes are con-
nected to one another. Thus, the similarity between
drug combination Dp and Dq can be measured based
on how Gp and Gq match to each other. In match-
ing such graphs, we consider SDSs so that drugs that
are similar to each other should be matched, and the
graph matching procedure should maximize the overall
SDSs from matched drugs. The underlying assumption
is that if two drug combinations share similar drugs,
they could have similar ADRs. Figure 1 illustrates the
idea of complete graph matching for two drug combi-
nations, in which the drugs connected by dash lines
are matched between Dp and Dq. The similarity cal-
culated from graph matching over two drug combi-
nations, denoted as Sgm, will the sum of SDSs from
matched drugs. Sgm will be further converted to a valid
kernel, denoted as Kgm.
Graph matching algorithm for Kgm
The drug combination graph matching problem can be
solved as a well known linear sum assignment problem
(LSAP) [21]. The objective is to minimize the total
cost of matching vertices in two graphs, and thus to
find the graph matching with minimal total cost. In
the case of high-order drug combinations, we define
the cost of matching two drugs di and dj as the dis-
similarity between the drugs, that is,
cost(di, dj) = 1− SDS(di, dj), (3)
where cost(di, dj) is the cost between di and dj, SDS
can be either SDS2d or SDScm. Thus, if two drugs
are very similar (i.e., large SDS), the cost of match-
ing them will be small and therefore they are more
likely to be matched.
Therefore, the graph matching can be solved by solv-
ing the following LSAP problem:
min
X
trace(C(Gp,Gq)X
T)
subject to X ∈ P ,
P :={X | X ∈ Rkp×kq , Xi,j ∈ {0, 1},
kp∑
i=1
Xi,j ≤ 1,
kq∑
j=1
Xi,j ≤ 1,
kp∑
i=1
kq∑
j=1
Xi,j = min(kp, kq)},
(4)
where trace() is the trace of a matrix; and kp and kq
are the number of vertices in Gp and Gq (and thus the
order of Dp and Dq), respectively; C(Gp,Gq) ∈ R
kp×kq
is the pairwise drug-matching cost matrix for two
drug combinationsDp andDq (C(i, j) = cost(dpi, dqj),
dpi ∈ Dp, dqj ∈ Dq). In Problem 4,X is the assignment
matrix to match Gp and Gq (i.e., to assign a vertex in
Gp to a vertex in Gq), in which all the values are ei-
ther 0 or 1, both the row sum and the column sum are
either 0 or 1 (i.e., a vertex is either matched or not;
if it is matched, it is matched to only one vertex in
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the other graph), and thus the sum of all the values is
exactly the minimal of kp and kq (i.e., the vertices in
the small graph have to be all matched). Essentially,
X assigns each of the vertices in the smaller graph of
Gp and Gq to exactly one vertex in the larger graph.
The optimization problem in 4 can be solved by the
Hungarian algorithm [22]. The drug-combination sim-
ilarity Sgm is then calculated as
Sgm(Dp, Dq) = trace(J − C(Gp,Gq)X
T), (5)
where J ∈ Rkp×kq is a matrix of all 1’s.
The drug-combination similarity matrix Sgm is al-
ways symmetric but not necessarily positive semi-
definite, and thus not always a valid kernel. To convert
Sgm to a valid kernel Kgm, we follow the approach in
Saigo et al.[23]. Specifically, we first conduct an eigen-
value decomposition on Sgm, subtract from the diago-
nal of the eigenvalue matrix its smallest negative eigen-
value, and reconstruct the original matrix from the al-
tered decomposition. The resulted matrix is positive,
semi-definite, and is used as Kgm.
Convolutional drug-combination kernels
Drug combination kernels from common drugs
We define a drug-combination kernel, denoted as Kcd,
based on common drugs among drug combinations.
Kcd is calculated as the Tanimoto coefficient over the
sets of drugs in the drug combinations, that is,
Kcd(Dp, Dq) = Tanimoto(Dp, Dq), (6)
where Tanimoto() is defined as in Equation 1. It has
been proved that Tanimoto coefficient is a valid ker-
nel function [24]. Kcd essentially measures the propor-
tion of shared common drugs among two drug com-
binations. The underlying assumption is that if two
drug combinations share many common drugs, they
are likely to have similar properties.
To further enhance the similarity between two drug
combinations from their common drugs, we also de-
fine an order-2 Kcd of drug combinations, denoted as
K
(2)
cd (Kcd in Equation 6 is correspondingly referred
to as order-1 Kcd and denoted as K
(1)
cd ). We first
represent a drug combination D = {d1, d2, · · · , dk}
by all its single drugs and drug pairs, denoted as
D
(2) = {d1, d2, · · · , dk, (d1, d2), (d1, d3), · · · , (dk−1, dk)}.
Thus, K
(2)
cd on two drug combinations Dp and Dq can
be calculated as the Tanimoto coefficient on D
(2)
p and
D
(2)
q , that is,
K
(2)
cd (Dp, Dq) = Tanimoto(D
(2)
p , D
(2)
q ). (7)
Intuitively, K
(2)
cd better differentiates drug combina-
tions with many shared drugs from those with fewer
shared drugs than K
(1)
cd . We only extend Kcd to order
2 since higher-order extension does not lead to bet-
ter performance according to our experimental results.
According to Equation 6, when the order becomes
much higher, Tanimoto(D
(n)
p , D
(n)
q ) may become very
small due to a rapid combinatorial growth in the de-
nominator and the insufficient common drug n-tuples
(i.e., the number in the nominator). Thus, Kcd with
extension to much higher order may lose the ability
to differentiate drug combinations that contain more
common drugs.
Drug combination kernels from drug similarities
The drug combination similarities can also be mea-
sured by the average drug similarities. The hypothesis
is that if two drug combinations have drugs that are
similar on average, they may share similar properties.
If two drug combinations have drugs that are similar
on average, they may share similar properties. There-
fore, we define an average-drug-similarity based kernel
for drug combinations, denoted as Kds, as follows,
Kds(Dp, Dq) =
1
kpkq
∑
di∈Dp
∑
dj∈Dq
SDS(di, dj), (8)
where kp and kq are the order of Dp and Dq, respec-
tively, and SDS can be SDS2d or SDScm. Intuitively,
Kds tends to capture averaged and smoothed drug
combination similarities. It has been proved that as
long as the involved SDSs are valid kernels (i.e., posi-
tive semi-definite), Kds will also be a valid kernel [16].
Probabilistic drug combination kernels from drug sets
We apply an ensemble kernel for drug combinations
based on the idea as in [25]. The key idea is to use a
reproducing kernel to characterize sample similarities
(i.e., SDS), and to use a probabilistic distance in the
reproducing kernel Hilbert space (RKHS) to measure
the ensemble similarity. The resulted ensemble simi-
larity matrix is a valid kernel matrix, denoted as Kpb.
This ensemble involves an eigen value decomposition,
during which, it is possible that some similarity matri-
ces are deprecated numerically and it leads to defeats
in Kpb calculation. To deal with this issue, we increase
the diagonals of involved square matrices by a small
value to guarantee the positive semi-definite proper-
ties.
Materials
Mining drug combinations
We extract high-order drug combinations from FDA
Adverse Event Reporting System (FAERS) [26]. We
Chiang et al. Page 5 of 11
use myopathy as the ADR of particular interest, and
extract 64,892 case (myopathy) events, in which pa-
tients report myopathy after taking multiple drugs,
and 1,475,840 control (non-myopathy) events, in which
patients do not report myopathy after taking drugs.
Each of these events involves a combination of more
than one drug.
Among all the involved drug combinations, 10,250
unique drug combinations appear in both case and
control events. For those 10,250 drug combinations,
we use Odds Ratio (OR) to quantify their ADR risks.
The OR for a drug combination D is defined based on
the contingency table 2, that is, it is the ratio of the
following two values: 1). the odds that the ADR oc-
curs when D is taken (i.e.,
n1
m1
in Table 2); and 2). the
odds that the ADR occurs when D is not taken (i.e.,
n2
m2
in Table 2). OR < 1 indicates the decreased risk
of ADR after a patient takes the drug combination,
OR = 1 indicates no risk change, and OR > 1 indicates
the increased risk. In the 10,250 drug combinations,
8,986 combinations have OR > 1 and 1,264 combina-
tions have OR < 1. These two sets of drug combinations
are denoted asM0 andN 0, respectively. In addition to
these combinations, there are 27,387 unique drug com-
binations that only appear in case events and 621,449
unique drug combinations that only appear in control
events. These two sets are denoted asM+ and N−, re-
spectively. The set of drug combinations in case events
is denoted as M (i.e., M = M+ ∪M0), and the set
of drug combinations in control events is denoted asN
(i.e., N = N−∪N 0). All these four sets together define
a high-order drug combination dataset from FAERS,
denoted as DFAERS. Table 3 presents the statistics of
DFAERS.
Training data generation
As shown in Table 3, M+ and M0 of DFAERS have
fewer drug combinations than N− and N 0, and the
drug combinations in M+ are very infrequent (aver-
age frequency 1.402). To use more frequent and more
confident drug combinations from case events, we fur-
ther pruned drug combinations from M+ and M0 as
follows. FromM+, we retained the top 1,000 most fre-
quent drug combinations. For M0, we applied right-
tailed Fisher’s exact test on the drug combinations to
further test the significance of their ORs at 5% signifi-
cance level. Then we retained drug combinations with
statistically significant ORs. Thus, the prunedM+ and
M0 contain statistically confident drug combinations,
which are very likely to induce myopathy, and there-
fore, these drug combinations are labeled as positive
instances for classification model learning.
We retained all 1,264 the drug combinations in N 0
because this set is not large and contains informative
drug combinations that may or may not induce my-
opathy. We further prune N− and retain the top most
frequent drug combinations. The drug combinations
from N 0 and the pruned N− are labeled as negative
instances. To make the positive and negative train-
ing sets balance, we retained 2,200 drug combinations
from N−. The pruned dataset from DFAERS is denoted
as D∗. Table 3 presents the description of D∗. D∗ is
the set of labeled drug combinations that are used for
model learning. In D∗, there are in total 1,210 drugs
involved. 71 out of these 1,210 drugs induce myopa-
thy on their own based on the Side Effect Resource
(SIDER) [27]. This set of 71 drugs is denoted as DMyo.
Evaluation protocol and metrics
The performance of the different methods is evalu-
ated through five-fold cross validation. The dataset is
randomly split into five folds of equal size (i.e., same
number of drug combinations). Four folds are used for
model training and the rest fold is used for testing.
This process is performed five times, with one fold for
testing each time. The final result is the average out
of the five experiments.
We use accuracy, precision, recall, F1 and AUC to
evaluate the performance of the methods. Accuracy
is defined as the fraction of all correctly classified in-
stances (i.e., true positives and true negatives) over all
the instances in the testing set. Precision is defined
as the fraction of correctly classified positive instances
(i.e., true positives) over all instances that are classi-
fied as positive instances (i.e., true positives and false
positives). Recall is the fraction of correctly classified
positive instances (i.e., true positives) over all positive
instances in the testing set (i.e., true positives and false
negatives). F1 is the harmonic mean of precision and
recall. AUC score is the normalized area under the
curve that plots the true positives against the false
positives for different thresholds for classification [28].
Larger accuracy, precision, recall, F1 and AUC values
indicate better classification performance.
Results
Overall performance
Table 4 presents the performance comparison among
the four different kernels in combination with differ-
ent single drug similarities on dataset D∗. Kernel Kgm
with SDScm outperforms others in three (i.e., accuracy,
F1 and AUC) out of five evaluation metrics. Specifi-
cally, in accuracy, Kgm with SDScm outperforms the
second best kernel Kgm with SDS2d at 0.84%. In F1,
Kgm with SDScm outperforms the second best kernel
Kgm with SDS2d and Kds with SDScm at 0.98%. In
AUC, Kgm with SDScm outperforms the second best
kernel order-2 Kcd at 0.33%. In precision and recall,
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Kgm with SDScm is the second best kernel, whereas
Kds with SDScm and Kds with SDS2d, respectively, is
the best one. Overall, Kgm with SDScm has the best
performance compared to other kernels. This indicates
that it is effective to classify drug combinations by rep-
resenting and comparing them as graphs (i.e., a set of
drugs and their co-medication relation within the set),
and measuring such graph similarities using their opti-
mal matching (i.e., the optimal correspondence among
drugs). In the following discussion, we use Kcmgm to rep-
resent Kgm with SDScm. More experimental results on
other datasets are available in the supplementary ma-
terials (see Additional file 1).
SDS performance
Table 4 shows that SDScm on average outperforms
SDS2d across different kernels (with a few exceptions
on in precision for Kds and Kpb). SDS2d considers drug
intrinsic 2D structures. However, drug efficacy and side
effects are the results of many complicated interactions
and processes among drugs and various bioentities,
which may not be sufficiently explained only by drug
2D structures. Compared to SDS2d, SDScm measures
drug similarity based on their co-medication patterns,
which could be regarded as a high-level abstraction
and representation of drug therapeutic properties that
may or may not be explicitly explained by each drug
and its intrinsic properties independently.
In Kcd, order-2 representation (i.e., in K
(2)
cd ) for drug
combinations outperforms order-1 representation (i.e.,
in K
(1)
cd ). In order-2 representation, in addition to sin-
gle drugs, drug pairs are also used as a feature for a
drug combination, which stresses the signals in drug
combinations. This also conforms to common observa-
tions in other applications [29], in which higher-order
features improve classification performance.
Classification
Figure 2 and 3 present the Kcmgm prediction values
with respect to drug combination orders. In Figure 2,
M+ drug combinations have higher orders (on aver-
age 7.615 as in Table 3), and higher and mostly pos-
itive prediction values, while N− drug combinations
have lower orders (on average 2.678), and lower and
mostly negative prediction values. Meanwhile, the mis-
classification typically happens on N− drug combina-
tions of higher orders, and on M+ drug combinations
of lower orders. Similar trends apply forM0 and N 0 in
Figure 3. This indicates that Kgm and SDScm together
are able to learn and make predictions that correspond
to drug combination orders. In addition, drug combi-
nation order is correlated with their ADR labels.
Figure 4 presents the Kcmgm prediction values with re-
spect to drug combination frequencies for M+ and
N−. M+ drug combinations have lower frequencies
(on average 5.520 as in Table 3), and higher and
mostly positive prediction values, while N− drug com-
binations have higher frequencies (on average 42.082),
and lower and mostly negative prediction values. For
N−, the mis-classification typically happens on lower-
frequency drug combinations (the mis-classification for
M+ does not show strong patterns with respect to
drug combination frequencies). As for M+ and N−,
drug combination frequencies are used to define ADR
labels. Figure 4 shows that Kcmgm together are able to
learn and make predictions that correspond to drug
combination frequencies and thus ADR labels.
Figure 5 presents the Kcmgm prediction values with re-
spect to OR values forM0 and N 0.M0 drug combina-
tions have higher OR values and also higher and mostly
positive prediction values, whileN 0 drug combinations
have lower OR values and also lower and mostly neg-
ative prediction values. For N 0, the mis-classification
typically happens on drug combinations of higher OR
values (close to 1 and thus more lean toward ADR;
the mis-classification forM0 does not show strong pat-
terns with respect to OR values). As we use OR to define
ADR labels onM0 andN 0, Figure 5 showsKcmgm is able
to make reasonably accurate prediction values on the
drug combinations.
DMyo drug enrichment
Table 5 presents the average percentage of DMyo drugs
among all the drug combinations. For each drug com-
bination, the percentage is calculated as the number of
its drugs that can cause myopathy on their own (i.e.,
drugs in DMyo) divided by the drug combination order.
As Table 5 shows, top-10 mis-classified N drug combi-
nations (i.e., N˜ 10+) have almost twice as many DMyo
drugs (30.7%) as those in N (15.6%), and even more
than those in M drug combinations (24.3%). In ad-
dition, mis-classified N drug combinations (i.e., N˜+)
also have significantly more DMyo drugs (18.6%) than
those in N (15.6%). Since Kcmgm matches similar drugs,
high DMyo drug enrichment could be a primary reason
for the mis-classification.
Top predictions
Top mis-classification on N
Table 6 lists the top-10 (in terms of prediction values)
drug combinations in N (i.e., without myopathy) that
are mis-classified as positive (i.e., with myopathy) by
Kcmgm. For those drug combinations which appear inN
0,
we present their OR values, otherwise only frequencies.
Those top mis-classified N drug combinations contain
many single drugs, which on their own can induce my-
opathy (i.e., in DMyo, bold in Table 6). As a matter of
fact, the percentage of DMyo drugs in top mis-classified
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N drug combinations is significantly higher than av-
erage. In Table 6, one special mis-classified N drug
combination is {lansoprazole omeprazole pantoprazole
rabeprazole}, which does not contain any DMyo drugs.
This set of drugs is commonly used as proton pump
inhibitors (PPIs) to decrease the amount of acid pro-
duced in the stomach. Some case studies show evidence
of causality between the PPI drug class and myopa-
thy [30, 31].
Top prediction on M
Table 7 presents the top-10 correctly predictedM drug
combinations by Kcmgm. These drug combinations are
significantly enriched with DMyo drugs (i.e., drugs that
can induce myopathy on their own). As Table 5 shows,
M˜10+ has the most DMyo drugs (89.8%) compared
to all the other sets and significantly more than M.
In particular, all of these combinations contain statin
drugs (e.g., atorvastatin, simvastatin and rosuvastatin,
etc.). These statin-related drugs have been studied in
literature as a drug class that has high possibilities
to induce myopathy [32, 33]. In addition, in Table 7,
4 out of the 6 M0 drug combinations among top 10
(i.e., the drug combinations that have OR values) have
their OR values higher than average in M0 (31.998 as
in Table 3), and 3 out of the 4 M+ drug combina-
tions among top 10 (i.e., the drug combinations that
do not have OR values) have their frequency higher
than average in M+ (5.520 as in Table 3). In addi-
tion, among the top-20 drug combinations predicted
by Kcmgm, 7 out of 12 M
0 drug combinations have their
OR values higher than average in M0, and 5 out of
8 M+ drug combinations have their frequency higher
than average in M+. The average OR values of the
top-10, top-20 and top-50 drug combinations fromM0
predicted by Kcmgm are 55.725, 42.956 and 42.114, re-
spectively, and they are all higher than the average
31.998 for M0. The average frequencies of the top-10,
top-20 and top-50 drug combinations from M+ pre-
dicted by Kcmgm are 8.250, 6.875 and 6.524, respectively,
and they are also all higher than the average 5.520 on
M+. This indicates that Kcmgm does learn signals from
M and correspondingly makes predictions.
Top non-DMyo prediction on M
Table 8 presents the top-10 correctly predictedM drug
combinations by Kcmgm that do not contain any drugs
from DMyo (i.e., do not contain drugs that can in-
duce myopathy on their own). 4 out of 7 drug com-
binations from M0 in this table have their OR values
higher than the average in M0 (31.998 as in Table 3).
The 3 drug combinations from M+ in this table have
their frequency lower than the average in M+ (5.520
as in Table 3) but very close. In Table 8, 8 out of
top-10 drug combinations include alendronate. Case
studies demonstrate that several events of severe mus-
cle pain, which is the common symptom of myopathy,
were reported after patients started therapy with al-
endronate [34], showing the association between the
medical treatment with alendronate and myopathy.
Discussions
The experimental results show that the new methods
with drug co-medication based single drug similarities
outperform other kernels, such as convolutional ker-
nels [16] and probabilistic kernels [25], and can ac-
curately predict whether a drug combination is likely
to induce ADRs of interest. The experimental results
demonstrate the advance of such single drug similari-
ties that leverage co-medication patterns among high-
order drug-drug interactions, and also inspire further
exploration that learns such similarities in a pure data-
driven fashion without pre-defined kernels, for exam-
ple, via manifold learning. Further research would also
include learning drug representations in a data-driven
fashion such that the representations better quantify
drug similarities in terms of their co-medication pat-
terns. Deep learning would be an optimistic option for
such drug representation learning.
Conclusions
In this manuscript, SVM-based classification methods
were developed to predict whether a drug combina-
tion of arbitrary orders is likely to induce adverse
drug reactions. Novel kernels over drug combinations
of arbitrary orders were developed for such classifi-
cation. These kernels were constructed from various
single-drug information including drug co-medication
patterns, and compare drug combination similarities
based on single drugs they have and the relations
among the single drugs. Specifically, a novel kernel
over drug combinations of arbitrary orders was devel-
oped based on graph matching over drug combination
graphs. A dataset from FDA Adverse Event Report-
ing System (FAERS) was constructed to test the new
methods. The experimental results demonstrated that
the new methods with drug co-medication based sin-
gle drug similarities and graph matching based kernels
achieve the best AUC as 0.912. The prediction also re-
vealed strong patterns among drug combinations (e.g.,
statin enriched) that may be highly correlated with
their induced ADRs.
List of abbreviations
DDI: Drug-Drug Interactions; ADR: Adverse Drug
Reaction; SDS: Single Drug Similarities; ECFP: Ex-
tended Connectivity Fingerprints; and OR: Odds Ra-
tio.
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Additional file 1 — Drug-Drug Interaction Prediction based on
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Tables
Table 1 Table of Notations
Notation Description
d Drug
D Drug combination
G Complete graph for a drug combination
SDS2d Single drug similarity from drug 2d structures
SDScm Single drug similarity based on co-medications
Kgm Kernel based on graph matching algorithm
Kcd Kernel from common drugs
Kds Kernel from drug similarities
Kpb Probabilistic drug combination kernel
Table 2 Contingency Table
OR =
n1
m1
/ n2
m2
ADR no ADR total
D n1 m1 n1 +m1
\D n2 m2 n2 +m2
total n1 + n2 m1 +m2 n1 + n2 +m1 +m2
In the table, n1 is the number of events where D is taken with ADR
occurring; m1 is the number of events where D is taken without
ADR occurring; n2 is the number of events where D is not taken
with ADR occurring; and m2 is the number of events where D is
not taken without ADR occurring, respectively.
Table 3 Data Statistics
dataset stats
N M
N− N 0 M0 M+
#{D} 621,449 1,264 8,986 27,387
#{d} 1,209 417 881 1,201
DFAERS avgOrd 6.100 2.351 3.588 7.096
avgFrq 1.761 225.317 13.730 1.402
avgOR - 0.546 16.343 -
#{D} 2,200 1,264 2,464 1,000
#{d} 562 417 692 679
D∗ avgOrd 2.678 2.351 3.809 7.615
avgFrq 42.082 225.317 20.565 5.520
avgOR - 0.546 31.998 -
In this table, “#{D}” and “#{d}” represent the number of drug
combinations and the number of involved drugs, respectively. In
each set of drug combinations, “avgOrd” is the the average or-
der; “avgFrq” is the average frequency; and “avgOR” represents
the average OR.
Table 4 Overall Performance Comparison
K Kgm Kcd Kds Kpb
SDS 2d cm ord-1 ord-2 2d cm 2d cm
acc 0.829 0.836 0.817 0.827 0.827 0.825 0.763 0.765
pre 0.889 0.892 0.879 0.878 0.893 0.865 0.810 0.770
rec 0.752 0.765 0.735 0.759 0.744 0.770 0.689 0.756
F1 0.815 0.823 0.801 0.814 0.812 0.815 0.744 0.763
AUC 0.898 0.912 0.907 0.909 0.900 0.900 0.843 0.853
In this table, “acc”, “pre”, “rec”, “F1” and “AUC” represent accu-
racy, precision, recall, F1 and the area under an receiver operating
characteristic curve, respectively. Kcd with “ord-1” corresponds to
K
(1)
cd , and Kcd with “ord-2” corresponds to K
(2)
cd .
Table 5 Average Percentage (%) of DMyo Drugs (K
cm
gm)
M˜10− M˜− M M˜
10+ N˜ 10+ N˜+ N N˜
10−
13.3 16.6 24.3 89.8 30.7 18.6 15.6 0.10
M˜− and N˜+ are the sets of all mis-classified drug combinations
in M and N by Kcmgm, respectively. M˜
10− is the set of the top-10
mis-classified drug combinations in M˜− and N˜ 10+ is the set of
the top-10 mis-classified drug combinations in N˜+ by Kcmgm. M˜
10+
and N˜ 10− are the sets of correctly classified drug combinations in
M and N with the top-10 highest and lowest prediction values,
respectively, by Kcmgm.
Table 6 Top mis-Classified N Drug Combinations by Kcmgm
N prd frq OR combinations
1 2.696 26 - atorvastatin fenofibrate rosiglitazone
simvastatin
2 2.507 26 - allopurinol amlodipine atorvastatin
levothyroxine naproxen omeprazole
simvastatin
3 1.878 22 - acetylsalicylicacid atorvastatin biso-
prolol clopidogrel ramipril simvastatin
4 1.855 27 - acetylsalicylicacid atenolol atorvastatin
furosemide lansoprazole lisinopril nitro-
glycerin
5 1.785 21 - citalopram clozapine isosorbidemonon-
itrate prochlorperazine simvastatin
zopiclone
6 1.750 - 0.842 amlodipine bisoprolol pravastatin
ramipril simvastatin spironolactone
warfarin
7 1.696 22 - amlodipine clopidogrel ibuprofen
omeprazole ramipril simvastatin
8 1.669 29 - bisoprolol flecainide ramipril simvas-
tatin
9 1.613 35 - aripiprazole atorvastatin bendroflume-
thiazide clozapine diazepam folicacid
furosemide iron lactulose lansoprazole
perindopril ramipril trimethoprim zopi-
clone
10 1.549 - 0.875 lansoprazole omeprazole pantoprazole
rabeprazole
In this table, “prd”, “frq” and “OR” represent prediction values,
frequency and odds ratio, respectively. Drugs in DMyo are marked
in bold.
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Figure 1 Graph matching for drug combinations
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Figure 5 OR values vs. predictions in Kcmgm
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Table 7 Top Predictions on M by Kcmgm
N prd frq OR Combinations
1 4.167 3 - atorvastatin lansoprazole pravas-
tatin rosuvastatin simvastatin
2 4.009 - 11.372 atorvastatin pravastatin rosuvas-
tatin simvastatin
3 3.776 - 50.043 atorvastatin fenofibrate metformin
pravastatin rosuvastatin simvas-
tatin
4 3.734 - 68.232 atorvastatin metformin pravastatin
rosuvastatin simvastatin
5 3.676 - 45.487 atorvastatin lovastatin rosuvas-
tatin simvastatin
6 3.618 - 136.470 atorvastatin pravastatin rosuvas-
tatin simvastatin tadalafil
7 3.573 9 - atorvastatin fenofibrate pravas-
tatin simvastatin
8 3.552 10 - atorvastatin ezetimibe fenofibrate
rosuvastatin
9 3.519 - 22.746 atorvastatin ezetimibe rosuvas-
tatin simvastatin
10 3.461 11 - atorvastatin lansoprazole pravas-
tatin simvastatin
In this table, “prd”, “frq” and “OR” represent prediction values,
frequency and odds ratio, respectively. Drugs in DMyo are marked
in bold.
Table 8 Top Predictions without DMyo Drugs by K
cm
gm
N prd frq OR Combinations
1 2.083 4 - calcium clonazepam colestipol pred-
nisone teriparatide
2 1.992 - 45.487 alendronate anastrozole deslorata-
dine hydrochlorothiazide lisinopril tri-
amterene valdecoxib vitaminc
3 1.968 - 17.058 alendronate raloxifene risedronate
teriparatide
4 1.960 - 90.978 alendronate amlodipine atenolol
clonazepam raloxifene teriparatide
5 1.901 - 45.489 alendronate fexofenadine hy-
drochlorothiazide omeprazole
prednisone risedronate triamterene
6 1.850 5 - alendronate fexofenadine levothyrox-
ine nabumetone oxybutynin
7 1.849 - 113.720 alendronate calcium esomeprazole
ibandronate levothyroxine rabepra-
zole
8 1.843 - 7.581 alendronate calciumgluconate teri-
paratide
9 1.838 - 22.744 alendronate calcium levothyroxine
raloxifene teriparatide
10 1.834 4 - calcium escitalopram iron ketorolac
raloxifene teriparatide
In this table, “prd”, “frq” and “OR” represent prediction values,
frequency and odds ratio, respectively.
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Performance on Other Datasets
Table 1 Data Statistics of D2000 and D4000
dataset stats
N M
N− N 0 M0 M+
#{D} 1,000 1,000 1,000 1,000
#{d} 1,000 369 596 679
D4000 avgOrd 2.585 2.340 4.770 7.615
avgFrq 62.545 264.898 5.957 5.520
avgOR - 0.451 60.994 -
#{D} 1,000 - - 1,000
#{d} 426 - - 679
D2000 avgOrd 2.585 - - 7.615
avgFrq 62.545 - - 5.520
avgOR - - - -
In this table, “#{D}” and “#{d}” represent the number of
drug combinations and the number of involved drugs, respec-
tively. In each set of drug combinations, “avgOrd” is the the
average order; “avgFrq” is the average frequency; and “avgOR”
represents the average OR.
In D∗, we retain the 1,000 drug combinations from
M+ and the 1,000 drug combinations with the largest
OR values from M0. The labels of these drug combina-
tions from M+ and M0 remain positive. From N− in
D∗, we retain the top 1,000 most frequent drug com-
binations. From N 0 in D∗, we retain the 1,000 drug
combinations with the smallest OR values. The labels
of these drug combinations from N− and N 0 remain
negative. The pruned dataset is denoted as D4000.
In D4000, we retain the 1,000 drug combinations from
M+ and 1,000 drug combinations from N− and the
labels remain positive and negative, respectively. This
pruned dataset based on D4000 is denoted as D2000.
Table 1 presents the statistics of D4000 and D2000.
Table 2 presents the overall performance comparison
on dataset D2000 and D4000. In both dataset, kernel
Kgm with SDScm outperforms others in accuracy, re-
call, F1 and AUC. Specifically, in accuracy, Kgm with
*Correspondence: xning@iupui.edu
4Department of Computer & Information Science, Indiana University -
Purdue University Indianapolis, 46202 Indianapolis, USA. Email:
xning@iupui.edu
Full list of author information is available at the end of the article
Table 2 Overall Performance Comparison of D2000
K Kgm Kcd Kds Kpb
SDS 2d cm ord-1 ord-2 2d cm 2d cm
acc 0.929 0.938 0.897 0.910 0.924 0.912 0.845 0.860
pre 0.954 0.959 0.941 0.942 0.957 0.917 0.839 0.860
D2000 rec 0.902 0.916 0.847 0.873 0.888 0.907 0.854 0.869
F1 0.927 0.937 0.891 0.906 0.921 0.912 0.846 0.861
AUC 0.973 0.976 0.964 0.968 0.970 0.960 0.920 0.926
acc 0.896 0.899 0.867 0.882 0.887 0.880 0.817 0.821
pre 0.933 0.939 0.928 0.930 0.944 0.903 0.838 0.816
D4000 rec 0.853 0.854 0.795 0.826 0.822 0.851 0.787 0.829
F1 0.891 0.894 0.856 0.875 0.879 0.876 0.812 0.822
AUC 0.953 0.962 0.954 0.958 0.951 0.945 0.898 0.908
In this table, “acc”, “pre”, “rec” and “AUC” represent accuracy,
precision, recall, and the area under an receiver operating charac-
teristic curve, respectively. In Kcd, “ord-1” is the kernel, in which
the similarity between two drug combinations is calculated by the
feature vectors, whose dimensions correspond to only one drug. As
for “ord-2”, the similarity between two drug combinations is calcu-
lated by the feature vectors, which have dimensions that correspond
to different pairs of drugs.
SDScm outperforms the second best kernel Kgm with
SDS2d at 0.97% and 0.33% in D
2000 and D4000, respec-
tively. In recall, Kgm with SDScm outperforms the sec-
ond best kernel Kgm with SDS2d at 1.55% and 0.12% in
D2000 and D4000, respectively. In F1, Kgm with SDScm
outperforms the second best kernel Kgm with SDS2d at
1.08% and 0.34% in D2000 and D4000, respectively. In
AUC, Kgm with SDScm outperforms the second best
kernel Kgm with SDS2d at 0.31% in D
2000 and out-
performs the second best kernel ord-2 Kcd at 0.42% in
D4000. In precision, the best kernel Kgm with SDScm
outperforms the second best kernel Kds with SDS2d
at 0.21% in D2000, whereas the best kernel Kds with
SDS2d outperforms the second best kernel Kgm with
SDScm at 0.53% in D
4000. In three datasets, D2000,
D4000 and D∗, in general, Kgm with SDScm has the
best performance compared to other kernels with a few
exceptions. This may show the effectiveness to classify
drug combinations by measuring the similarities be-
tween graphs, which represent drug combinations.
In kernel Kgm and Kpb, SDScm outperforms SDS2d
on average. This indicates the consistency in three
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datasets of better capability to measure the similar-
ities based on co-medication patterns than drug 2D
structures. For kernel Kcd, ord-2 outperforms ord-1 in
both datasets as in D∗. This consists with our obser-
vation before. That is, the ord-2 representation, which
contains drug pairs as a feature, can emphasize the
co-occurrence patterns in drug combinations.
Author details
1Department of Computer & Information Science, Indiana University -
Purdue University Indianapolis, 46202 Indianapolis, USA. Email:
chiangwe@iupui.edu. 2Department of Biostatistics, Epidemiology and
Informatics, University of Pennsylvania, 19104 Philadelphia, USA. Email:
Li.Shen@pennmedicine.upenn.edu. 3Department of Biomedical Informatics,
Ohio State University, 43210 Columbus, USA. Email: Lang.Li@osumc.edu.
4Department of Computer & Information Science, Indiana University -
Purdue University Indianapolis, 46202 Indianapolis, USA. Email:
xning@iupui.edu.
